Tango Therapeutics, Inc. — Form 10-Q
Filed August 11, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Tango amended its Non-Employee Director Compensation Policy effective June 4, 2026. The policy specifies cash retainers ($45k base, plus committee/leadership roles), equity grants (75k options + 12.5k RSUs initial; 25k options + 4k RSUs annually), and a $750k annual cap ($1M in first year). No specific dollar changes, dollar amounts owed, or counterparties are disclosed in this document—it is a standard governance template.
Why this rating
Routine policy amendment with no quantified changes, new obligations, or financial impact disclosed. Boilerplate director governance.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.